Living Cell Technologies Ltd. (AU:1AI) has released an update.
Algorae Pharmaceuticals Limited has reported promising pre-clinical results for AI-116, a drug candidate aimed at treating dementia, which demonstrated a significant reduction in glutamate-induced toxicity, outperforming the existing FDA-approved drug Donepezil. The company has also identified unique gene modulations associated with neurodegenerative disorders following AI-116 treatment, and has initiated the process for an international patent while planning for upcoming clinical trials.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.
